Press Releases and Blog
Blog
Former Representative Altmire Joins Former U.S. Senator Pat Toomey In Cautioning Lawmakers Against Passing Proposals Targeting Pharmacy Benefits
In case you missed it, Jason Altmire, former Democratic three-term U.S. Representative from Pennsylvania and current adjunct professor at Texas Tech University, explains why so-called
ICYMI: JC Scott In RealClearHealth: Amid Rising Health Care Premiums, Misguided Legislation Would Raise Costs Even Higher
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association, discusses how recent proposals being considered by Congress targeting
ICYMI: Former U.S. Senator Pat Toomey: Before Targeting PBMs, Republicans Should Consider The Unintended Consequences
In case you missed it, Pat Toomey, former U.S. Senator from Pennsylvania, cautioned lawmakers against legislation targeting pharmacy benefit companies and policies that meddle with
New JAMA Article Affirms Misguided Policies Targeting Pharmacy Benefit Companies Would Weaken Negotiating Power Against Big Pharma, Undercut Savings
A team of professors from Johns Hopkins University, Georgetown Law School, and Utah University College of Pharmacy published in the JAMA Health Forum a new
“Delinking” Legislation Provides Big Pharma With $32 Billion Bailout Annually While Costing Patients And Families Up To $27 Billion In Increased Premiums
The so-called “delinking” policy made news last week with the introduction of H.R. 6283. Among several glaring problems — including a rejection of free market
ICYMI: Competitive Enterprise Institute Explains How Pharmacy Benefit Companies Lower Health Care Costs
In case you missed it, the Competitive Enterprise Institute (CEI) released a new video, “Pharmacy Benefit Managers and Healthcare Costs: Not a Policy Paper, Just
Press Releases
PCMA Releases New Policy Recommendations to Remove Barriers to Biosimilars, Lower Drug Costs
New Research Paper Demonstrates Declining Biosimilars Prices and Increasing Health Plan Coverage (Washington, D.C.) — Pharmacy benefit managers, PBMs, support the proliferation and use of
PCMA Launches Educational Campaign in Honor of World Diabetes Day
(Washington, D.C.) — In honor of World Diabetes Day, the Pharmaceutical Care Management Association (PCMA) has launched a new phase of the OnYourRxSide campaign that
Express Scripts President Amy Bricker Becomes PCMA Board Chair
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) is pleased to announce that Amy Bricker, RPh, president of Express Scripts, has assumed the role
New PCMA Podcast Highlights Importance of Prescription Drug Rebates
(Washington, D.C.) — The Pharmaceutical Care Management Association’s (PCMA) podcast, The Pharmacy Benefit, released a new episode, “Understanding Prescription Drug Rebates.” The podcast episode, hosted by
New Data Reveal a Stable Independent Pharmacy Market
(Washington, D.C.) — New data from the National Council for Prescription Drug Programs (NCPDP) database, highlighted today by the Pharmaceutical Care Management Association (PCMA), shows that the
Congressional Budget Office Confirms The Insulin Act Increases Health Care Costs
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released the following statement on the Congressional Budget Office’s (CBO) estimate that The INSULIN Act
Don’t Be Fooled: Big Pharma Keeps the Vast Majority of the Rx Dollar
A simple fact is often lost in the din of the current drug pricing debate going on in Washington D.C. and around the country: Drug
Disclosure Requirements Could Impact Manufacturer Rebates
New report finds a potential result of disclosure requirements could increase federal government costs by $134 billion over 10 years Congress continues to consider proposals
New PCMA Rx Research Corner Blog Post: Dr. Lawton Robert Burns Sheds Light on the Role of PBMs
“PBMs promote competition in healthcare and help to reduce prices,” said Lawton Robert Burns Hot Off the Presses: University of Pennsylvania Wharton School professor Lawton
New Legislation Aims to Increase Competition in U.S. Biosimilar Market
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market. Bringing more biosimilars to market, over time, will allow PBMs to more effectively
Eliminating Spread Pricing Would Lead to Higher Costs and Fewer Choices for America’s Employers
What is spread pricing? Spread pricing is a contract option for employers and plan sponsors who want their pharmacy benefit company to carry the risk that pharmacies
Misguided Legislation Puts Innovation and Savings Delivered by Pharmacy Benefit Industry at Risk
In case you missed it, PCMA President and CEO JC Scott joined Prime Therapeutics’ webinar Beyond the Script: PBM Hot Topics in D.C. to discuss how
Big Pharma Returns with Self-Serving Policies Already Rejected by Congress
While Big Pharma pushes misguided policies targeting pharmacy benefits as part of a blame game designed to keep prescription drug prices high, former Members of
A World Without Pharmacy Benefit Companies? Ask the Department of Labor
The vast majority of employers and public health programs voluntarily work with pharmacy benefit companies to manage pharmacy benefits. So, what happens when a health
Robust U.S. Biosimilar Market Will Encourage Competition and Lower Prescription Drug Costs for Patients
With the recent launch of a new adalimumab biosimilar, the U.S. biosimilar market is becoming more competitive, increasing the potential for these more affordable options to play
94 Percent Of The Drug Dollar Is Retained By Drug Manufacturers, Drug Wholesalers, And Pharmacies
A simple fact is often lost in the din of the current drug pricing debate going on in Washington D.C. and around the country: Drug